247 related articles for article (PubMed ID: 25398695)
1. Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease.
Ooi J; Hayden MR; Pouladi MA
Mol Neurobiol; 2015 Dec; 52(3):1850-1861. PubMed ID: 25398695
[TBL] [Abstract][Full Text] [Related]
2. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.
Garcia-Miralles M; Ooi J; Ferrari Bardile C; Tan LJ; George M; Drum CL; Lin RY; Hayden MR; Pouladi MA
Exp Neurol; 2016 Apr; 278():4-10. PubMed ID: 26825854
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
[TBL] [Abstract][Full Text] [Related]
4. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
5. Acute exposure to chlorpyrifos caused NADPH oxidase mediated oxidative stress and neurotoxicity in a striatal cell model of Huntington's disease.
Dominah GA; McMinimy RA; Kallon S; Kwakye GF
Neurotoxicology; 2017 May; 60():54-69. PubMed ID: 28300621
[TBL] [Abstract][Full Text] [Related]
6. Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells.
Ribeiro M; Rosenstock TR; Cunha-Oliveira T; Ferreira IL; Oliveira CR; Rego AC
Free Radic Biol Med; 2012 Nov; 53(10):1857-67. PubMed ID: 22982598
[TBL] [Abstract][Full Text] [Related]
7. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin.
Naia L; Ribeiro M; Rodrigues J; Duarte AI; Lopes C; Rosenstock TR; Hayden MR; Rego AC
Neuropeptides; 2016 Aug; 58():73-81. PubMed ID: 26876526
[TBL] [Abstract][Full Text] [Related]
8. Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease.
Valencia A; Sapp E; Kimm JS; McClory H; Reeves PB; Alexander J; Ansong KA; Masso N; Frosch MP; Kegel KB; Li X; DiFiglia M
Hum Mol Genet; 2013 Mar; 22(6):1112-31. PubMed ID: 23223017
[TBL] [Abstract][Full Text] [Related]
9. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
Zala D; Benchoua A; Brouillet E; Perrin V; Gaillard MC; Zurn AD; Aebischer P; Déglon N
Neurobiol Dis; 2005 Dec; 20(3):785-98. PubMed ID: 16006135
[TBL] [Abstract][Full Text] [Related]
10. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
[TBL] [Abstract][Full Text] [Related]
11. Omi / HtrA2 is relevant to the selective vulnerability of striatal neurons in Huntington's disease.
Inagaki R; Tagawa K; Qi ML; Enokido Y; Ito H; Tamura T; Shimizu S; Oyanagi K; Arai N; Kanazawa I; Wanker EE; Okazawa H
Eur J Neurosci; 2008 Jul; 28(1):30-40. PubMed ID: 18662332
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
13. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death.
Roze E; Betuing S; Deyts C; Marcon E; Brami-Cherrier K; Pagès C; Humbert S; Mérienne K; Caboche J
FASEB J; 2008 Apr; 22(4):1083-93. PubMed ID: 18029446
[TBL] [Abstract][Full Text] [Related]
14. Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells--protective effect of cystamine and creatine.
Ribeiro M; Silva AC; Rodrigues J; Naia L; Rego AC
Toxicol Sci; 2013 Dec; 136(2):487-99. PubMed ID: 24008831
[TBL] [Abstract][Full Text] [Related]
15. Mono- and Biallelic Inactivation of Huntingtin Gene in Patient-Specific Induced Pluripotent Stem Cells Reveal HTT Roles in Striatal Development and Neuronal Functions.
Louessard M; Cailleret M; Jarrige M; Bigarreau J; Lenoir S; Dufour N; Rey M; Saudou F; Deglon N; Perrier AL
J Huntingtons Dis; 2024; 13(1):41-53. PubMed ID: 38427495
[TBL] [Abstract][Full Text] [Related]
16. Twist1 Plays an Anti-apoptotic Role in Mutant Huntingtin Expression Striatal Progenitor Cells.
Jen WP; Chen HM; Lin YS; Chern Y; Lee YC
Mol Neurobiol; 2020 Mar; 57(3):1688-1703. PubMed ID: 31813126
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography.
Richards G; Messer J; Waldvogel HJ; Gibbons HM; Dragunow M; Faull RL; Saura J
Brain Res; 2011 Jan; 1370():204-14. PubMed ID: 21075085
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
[TBL] [Abstract][Full Text] [Related]
19. Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.
Lu XH; Mattis VB; Wang N; Al-Ramahi I; van den Berg N; Fratantoni SA; Waldvogel H; Greiner E; Osmand A; Elzein K; Xiao J; Dijkstra S; de Pril R; Vinters HV; Faull R; Signer E; Kwak S; Marugan JJ; Botas J; Fischer DF; Svendsen CN; Munoz-Sanjuan I; Yang XW
Sci Transl Med; 2014 Dec; 6(268):268ra178. PubMed ID: 25540325
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
